Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans

Andrew Saykin, Li Shen, Tatiana Foroud, Steven G. Potkin, Shanker Swaminathan, Sungeun Kim, Shannon L. Risacher, Kwangsik Nho, Matthew J. Huentelman, David W. Craig, Paul M. Thompson, Jason L. Stein, Jason H. Moore, Lindsay A. Farrer, Robert C. Green, Lars Bertram, Clifford R. Jack, Michael W. Weiner

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

The role of the Alzheimer's Disease Neuroimaging Initiative Genetics Core is to facilitate the investigation of genetic influences on disease onset and trajectory as reflected in structural, functional, and molecular imaging changes; fluid biomarkers; and cognitive status. Major goals include (1) blood sample processing, genotyping, and dissemination, (2) genome-wide association studies (GWAS) of longitudinal phenotypic data, and (3) providing a central resource, point of contact and planning group for genetics within the Alzheimer's Disease Neuroimaging Initiative. Genome-wide array data have been publicly released and updated, and several neuroimaging GWAS have recently been reported examining baseline magnetic resonance imaging measures as quantitative phenotypes. Other preliminary investigations include copy number variation in mild cognitive impairment and Alzheimer's disease and GWAS of baseline cerebrospinal fluid biomarkers and longitudinal changes on magnetic resonance imaging. Blood collection for RNA studies is a new direction. Genetic studies of longitudinal phenotypes hold promise for elucidating disease mechanisms and risk, development of therapeutic strategies, and refining selection criteria for clinical trials.

Original languageEnglish
Pages (from-to)265-273
Number of pages9
JournalAlzheimer's and Dementia
Volume6
Issue number3
DOIs
StatePublished - May 2010

Fingerprint

Genome-Wide Association Study
Neuroimaging
Alzheimer Disease
Biomarkers
Phenotype
Magnetic Resonance Imaging
Molecular Imaging
Patient Selection
Longitudinal Studies
Cerebrospinal Fluid
Clinical Trials
Genome
RNA
Therapeutics

Keywords

  • Alzheimer's disease
  • Alzheimer's Disease Neuroimaging Initiative (ADNI)
  • Cerebrospinal fluid (CSF)
  • Copy number variation (CNV)
  • Genome-wide association studies (GWAS)
  • Magnetic resonance imaging (MRI)
  • Mild cognitive impairment (MCI)

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology
  • Medicine(all)

Cite this

Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes : Genetics core aims, progress, and plans. / Saykin, Andrew; Shen, Li; Foroud, Tatiana; Potkin, Steven G.; Swaminathan, Shanker; Kim, Sungeun; Risacher, Shannon L.; Nho, Kwangsik; Huentelman, Matthew J.; Craig, David W.; Thompson, Paul M.; Stein, Jason L.; Moore, Jason H.; Farrer, Lindsay A.; Green, Robert C.; Bertram, Lars; Jack, Clifford R.; Weiner, Michael W.

In: Alzheimer's and Dementia, Vol. 6, No. 3, 05.2010, p. 265-273.

Research output: Contribution to journalArticle

Saykin, A, Shen, L, Foroud, T, Potkin, SG, Swaminathan, S, Kim, S, Risacher, SL, Nho, K, Huentelman, MJ, Craig, DW, Thompson, PM, Stein, JL, Moore, JH, Farrer, LA, Green, RC, Bertram, L, Jack, CR & Weiner, MW 2010, 'Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans', Alzheimer's and Dementia, vol. 6, no. 3, pp. 265-273. https://doi.org/10.1016/j.jalz.2010.03.013
Saykin, Andrew ; Shen, Li ; Foroud, Tatiana ; Potkin, Steven G. ; Swaminathan, Shanker ; Kim, Sungeun ; Risacher, Shannon L. ; Nho, Kwangsik ; Huentelman, Matthew J. ; Craig, David W. ; Thompson, Paul M. ; Stein, Jason L. ; Moore, Jason H. ; Farrer, Lindsay A. ; Green, Robert C. ; Bertram, Lars ; Jack, Clifford R. ; Weiner, Michael W. / Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes : Genetics core aims, progress, and plans. In: Alzheimer's and Dementia. 2010 ; Vol. 6, No. 3. pp. 265-273.
@article{aafa626c0de0478295875f554138b452,
title = "Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans",
abstract = "The role of the Alzheimer's Disease Neuroimaging Initiative Genetics Core is to facilitate the investigation of genetic influences on disease onset and trajectory as reflected in structural, functional, and molecular imaging changes; fluid biomarkers; and cognitive status. Major goals include (1) blood sample processing, genotyping, and dissemination, (2) genome-wide association studies (GWAS) of longitudinal phenotypic data, and (3) providing a central resource, point of contact and planning group for genetics within the Alzheimer's Disease Neuroimaging Initiative. Genome-wide array data have been publicly released and updated, and several neuroimaging GWAS have recently been reported examining baseline magnetic resonance imaging measures as quantitative phenotypes. Other preliminary investigations include copy number variation in mild cognitive impairment and Alzheimer's disease and GWAS of baseline cerebrospinal fluid biomarkers and longitudinal changes on magnetic resonance imaging. Blood collection for RNA studies is a new direction. Genetic studies of longitudinal phenotypes hold promise for elucidating disease mechanisms and risk, development of therapeutic strategies, and refining selection criteria for clinical trials.",
keywords = "Alzheimer's disease, Alzheimer's Disease Neuroimaging Initiative (ADNI), Cerebrospinal fluid (CSF), Copy number variation (CNV), Genome-wide association studies (GWAS), Magnetic resonance imaging (MRI), Mild cognitive impairment (MCI)",
author = "Andrew Saykin and Li Shen and Tatiana Foroud and Potkin, {Steven G.} and Shanker Swaminathan and Sungeun Kim and Risacher, {Shannon L.} and Kwangsik Nho and Huentelman, {Matthew J.} and Craig, {David W.} and Thompson, {Paul M.} and Stein, {Jason L.} and Moore, {Jason H.} and Farrer, {Lindsay A.} and Green, {Robert C.} and Lars Bertram and Jack, {Clifford R.} and Weiner, {Michael W.}",
year = "2010",
month = "5",
doi = "10.1016/j.jalz.2010.03.013",
language = "English",
volume = "6",
pages = "265--273",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes

T2 - Genetics core aims, progress, and plans

AU - Saykin, Andrew

AU - Shen, Li

AU - Foroud, Tatiana

AU - Potkin, Steven G.

AU - Swaminathan, Shanker

AU - Kim, Sungeun

AU - Risacher, Shannon L.

AU - Nho, Kwangsik

AU - Huentelman, Matthew J.

AU - Craig, David W.

AU - Thompson, Paul M.

AU - Stein, Jason L.

AU - Moore, Jason H.

AU - Farrer, Lindsay A.

AU - Green, Robert C.

AU - Bertram, Lars

AU - Jack, Clifford R.

AU - Weiner, Michael W.

PY - 2010/5

Y1 - 2010/5

N2 - The role of the Alzheimer's Disease Neuroimaging Initiative Genetics Core is to facilitate the investigation of genetic influences on disease onset and trajectory as reflected in structural, functional, and molecular imaging changes; fluid biomarkers; and cognitive status. Major goals include (1) blood sample processing, genotyping, and dissemination, (2) genome-wide association studies (GWAS) of longitudinal phenotypic data, and (3) providing a central resource, point of contact and planning group for genetics within the Alzheimer's Disease Neuroimaging Initiative. Genome-wide array data have been publicly released and updated, and several neuroimaging GWAS have recently been reported examining baseline magnetic resonance imaging measures as quantitative phenotypes. Other preliminary investigations include copy number variation in mild cognitive impairment and Alzheimer's disease and GWAS of baseline cerebrospinal fluid biomarkers and longitudinal changes on magnetic resonance imaging. Blood collection for RNA studies is a new direction. Genetic studies of longitudinal phenotypes hold promise for elucidating disease mechanisms and risk, development of therapeutic strategies, and refining selection criteria for clinical trials.

AB - The role of the Alzheimer's Disease Neuroimaging Initiative Genetics Core is to facilitate the investigation of genetic influences on disease onset and trajectory as reflected in structural, functional, and molecular imaging changes; fluid biomarkers; and cognitive status. Major goals include (1) blood sample processing, genotyping, and dissemination, (2) genome-wide association studies (GWAS) of longitudinal phenotypic data, and (3) providing a central resource, point of contact and planning group for genetics within the Alzheimer's Disease Neuroimaging Initiative. Genome-wide array data have been publicly released and updated, and several neuroimaging GWAS have recently been reported examining baseline magnetic resonance imaging measures as quantitative phenotypes. Other preliminary investigations include copy number variation in mild cognitive impairment and Alzheimer's disease and GWAS of baseline cerebrospinal fluid biomarkers and longitudinal changes on magnetic resonance imaging. Blood collection for RNA studies is a new direction. Genetic studies of longitudinal phenotypes hold promise for elucidating disease mechanisms and risk, development of therapeutic strategies, and refining selection criteria for clinical trials.

KW - Alzheimer's disease

KW - Alzheimer's Disease Neuroimaging Initiative (ADNI)

KW - Cerebrospinal fluid (CSF)

KW - Copy number variation (CNV)

KW - Genome-wide association studies (GWAS)

KW - Magnetic resonance imaging (MRI)

KW - Mild cognitive impairment (MCI)

UR - http://www.scopus.com/inward/record.url?scp=77954021537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954021537&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2010.03.013

DO - 10.1016/j.jalz.2010.03.013

M3 - Article

C2 - 20451875

AN - SCOPUS:77954021537

VL - 6

SP - 265

EP - 273

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -